CD8+ T cells classically count as anti-tumourous cells and are a basis of modern therapies such as immune, CART, or bispecific antibody therapies, but many studies also show pro-tumourous abilities promoting tumour growth and immunosuppression. This evidence concerns the gene CD8A and neoplasm.